The remarks suggest that Eli Lilly’s initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment…
Eli Lilly said supply of its blockbuster diabetes drug Mounjaro has recently improved in the U.S. after widespread shortages.
The remarks suggest that Eli Lilly's efforts to expand manufacturing capacity for Mounjaro are paying off. Demand for the treatment is soaring, largely due to its off-label ability to cause significant weight loss. U.S. regulators could potentially approve the drug for weight loss this year, which could push up demand even more.During an earnings call Thursday, Eli Lilly executives said the company experienced tight supply for Mounjaro throughout most of the. Mounjaro raked in $1.
She noted that all doses of Mounjaro are now listed as available on the Food and Drug Administration's shortage database. Meanwhile, Mounjaro supply remains tight internationally, Ashkenazi added.Olympic bobsled gold medalist Steve Mesler to test physical, mental limit at NYC Marathon Ashkenazi pointed to the company's new facility in North Carolina, which is now"online" to provide additional drug assembly capacity. Eli Lilly has also invested more thanBut Eli Lilly CEO David Ricks said during the earnings call that the company is still"aggressively planning" further production build-up for Mounjaro and other drugs.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's stock rises as results beat expectations, Mounjaro sales surgeDrugmaker trims full-year outlook as it digests a string of recent acquisitions
Read more »
Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.The remarks suggest that Eli Lilly's initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment soars.
Read more »
Eli Lilly beats quarterly revenue estimates on Mounjaro strengthEli Lilly (LLY.N) beat Wall Street's revenue estimates for the third quarter on Thursday, lifted by strong demand for its diabetes drug Mounjaro that brought in over a billion dollars in sales.
Read more »
Eli Lilly beats quarterly revenue estimates on Mounjaro strengthEli Lilly beats quarterly revenue estimates on Mounjaro strength
Read more »
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlookEli Lilly reported revenue and adjusted earnings that topped expectations, lifted by $1.4 billion in sales from its blockbuster diabetes drug Mounjaro.
Read more »
Here are Thursday's biggest analyst calls: Amazon, Sunrun, Qualcomm, Eli Lilly, SolarEdge, Estee Lauder & moreHere are Thursday's biggest calls on Wall Street.
Read more »